ImmunoGen gets orphan drug designation for IMGN901 compound

Submit press release

Existing customer?
Log in

New customer?
Sign up

Latest Headlines
Research and Markets: The Report 'PV Innovation in North America'...
Research and Markets: Vietnam Telecommunications Services Market Report:...
Research and Markets: Indonesia Soft Drinks Review 2011: consumption,...
Northampton family thank Red Cross with generous donation to county...
Research and Markets: Malaysia Soft Drinks Review 2011: consumption,...
Simon Ward - The MPC is making another policy...

M2 Archive: Preview

You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.

ImmunoGen gets orphan drug designation for IMGN901 compound
9 March 2010 - US-based biotechnology company ImmunoGen Inc (NASDAQ: IMGN) announced yesterday that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC).
IMGN901 is an investigational agent...

If you want to view the full text, you must first purchase archive credits.
Return to Archives
New Search